Regulatory Compliance & Quality

Clinical evidence aligned with regulatory strategy across the product lifecycle

explore

Regulatory compliance across markets

Medical device development often requires clinical evidence that can support regulatory decisions in more than one market.
KCRI helps manufacturers and sponsors align clinical development, regulatory strategy and quality requirements across the product lifecycle, with experience in European and US regulatory environments.
Our focus is on consistent, traceable and interpretable clinical evidence that supports regulatory submissions, conformity assessment and post-market obligations.

Evidence strategy across markets

Regulatory requirements should be considered before clinical evidence is generated.
KCRI helps sponsors identify which evidence requirements can be addressed through a common clinical programme and where market-specific evidence or activities may be required. This helps reduce avoidable duplication while recognising that evidence accepted in one market may not fully satisfy the requirements of another.

Clinical development across EU and US markets.

EU MDR and European market

Under the EU MDR, clinical evidence must remain consistent and traceable throughout the device lifecycle – from clinical evaluation and conformity assessment to post-market surveillance and post-market clinical follow-up.
KCRI supports manufacturers in structuring and managing pre-market and post-market clinical development programmes that address these requirements.

FDA and US market

Clinical development for the US market should reflect the intended FDA regulatory pathway, applicable evidence expectations and requirements for clinical investigations.
KCRI supports manufacturers and sponsors in planning clinical development with the US regulatory strategy in mind, while identifying evidence that may also contribute to submissions in Europe and other markets.
Throughout study design and execution, we focus on data quality, traceability, consistency and interpretability to support readiness for regulatory review.

How we approach MDR compliance

MDR compliance requires coordination between clinical evidence, regulatory strategy and quality systems.

KCRI supports this integration across the full product lifecycle, from early development to post-market activities.

Lifecycle perspective

MDR compliance extends beyond initial certification.

It requires continuous alignment of clinical data, regulatory strategy and quality systems throughout the product lifecycle.

Managing regulatory risk early

Many regulatory problems begin before submission. They may arise from early assumptions, study design, evidence strategy or inconsistent data generated across studies and lifecycle stages.

Common challenges include:
• study design that is not aligned with the intended regulatory pathway;
• inconsistent clinical data across studies or development stages;
• poor alignment between clinical evaluation and post-market evidence;
• fragmented clinical, regulatory and quality activities;
• evidence programmes designed for one market without sufficient consideration of others.

KCRI addresses these risks by integrating clinical development, regulatory requirements and quality oversight from the beginning of the programme.

What this means for manufacturers

• consistent and interpretable clinical evidence;
• closer alignment between clinical development and regulatory strategy;
• improved readiness for regulatory review, audits and conformity assessment;
• better use of evidence across target markets;
• reduced risk of avoidable delays, rework and evidence gaps.

Advanced therapies and innovative clinical development

KCRI supports clinical research involving advanced therapies, including Advanced Therapy Medicinal Products (ATMPs) in Europe and cell and gene therapy programmes within the US regulatory environment.

Quality system

KCRI operates under certified quality and information security management systems, including ISO 9001 and ISO/IEC 27001, supporting consistent, controlled and secure clinical research operations.
Certification body: TÜV Rheinland®

Certified scope:
• selection of clinical trial sites;
• clinical and regulatory support, including GCP;
• planning, management and supervision of Phase I–IV clinical trials, including First-in-Human studies;
• independent, standardised analysis of angiographic images, intravascular ultrasound and ECG.

Discuss your clinical development programme

Contact KCRI to discuss how clinical development, regulatory strategy and quality oversight can be aligned across the intended markets learnmore@kcri.org

Careers

Learn about the career opportunities with KCRI

Work with KCRI